Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
69,337.79 +1,964.15 (+2.92%) CMC Crypto 200
1,453.75 -14.35 (-0.98%)
ME Jan 2025 2.000 call
| Previous close | 0.1500 |
| Open | 0.1000 |
| Bid | 0.0500 |
| Ask | 0.1000 |
| Strike | 2.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0500 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.66k |
- Thomson Reuters StreetEvents
Q4 2024 23andMe Holding Co. Earnings Call
Q4 2024 23andMe Holding Co. Earnings Call
GlobeNewswire23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review strategic alternatives that may be available to 23andMe to maxim
- GlobeNewswire
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activitySUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working direct
